LATEST PRICE
$442.24
H 442.90 · L 435.27
Vol 266K · May 18
COMPOSITE SCORE
50.3
out of 100
RECOMMENDATION
WATCH
CONFIDENCE
71%
MODULES RUN
8/8
May 18, 14:18 UTC
Top Signals
- • Analysed 3 articles over 7 days (1 sentiment-scored)
- • Average sentiment: +1.00 — Positive: 1, Neutral: 0, Negative: 0
- • Most bullish: "Billionaire Investor Takes New Stake In Thermo Fisher Scientific" (score +1.00)
- • CEO assessment: Strong leadership with a solid track record in driving growth and innovation.
- • Insider ownership: Moderate
Price History
showing 7 of 30 days
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| May 18, 2026 | $438.44 | 442.90 | 435.27 | $442.24 | +3.90 (+0.9%) | 266K |
| May 15, 2026 | $444.02 | 444.95 | 437.32 | $438.34 | -9.87 (-2.2%) | 2.0M |
| May 14, 2026 | $448.21 | 459.18 | 446.05 | $448.21 | +2.18 (+0.5%) | 2.1M |
| May 13, 2026 | $455.18 | 463.40 | 444.52 | $446.03 | -13.27 (-2.9%) | 2.8M |
| May 12, 2026 | $454.34 | 463.10 | 452.85 | $459.30 | +6.70 (+1.5%) | 3.1M |
| May 11, 2026 | $464.86 | 466.79 | 447.88 | $452.60 | -12.40 (-2.7%) | 4.0M |
| May 08, 2026 | $473.49 | 473.49 | 456.36 | $465.00 | -9.46 (-2.0%) | 3.9M |
Module Breakdown — May 18, 14:18 UTC
| Module | Score | Confidence | Signals |
|---|---|---|---|
| Sentiment |
90.0 |
15% | • Analysed 3 articles over 7 days (1 sentiment-scored) • Average sentiment: +1.00 — Positive: 1, Neutral: 0, Negative: 0 • Most bullish: "Billionaire Investor Takes New Stake In Thermo Fisher Scientific" (score +1.00) |
| Leadership |
85.0 |
65% | • CEO assessment: Strong leadership with a solid track record in driving growth and innovation. • Insider ownership: Moderate • CEO has been with the company since 2019 and has a strong execution record. • Consistent revenue growth and strategic acquisitions enhance competitive positioning. • Moderate insider ownership aligns interests with shareholders. • No significant governance scandals reported. |
| Moat |
85.0 |
65% | • Switching costs: High | Network effects: Moderate • Brand strength: High | Market position: Dominant • Strong brand recognition in life sciences • Extensive portfolio of patented products • High customer reliance on specialized equipment • Large-scale operations supporting pricing power |
| FinancialHealth |
58.0 |
85% | • Profitable: Net income $1651M • Slight revenue decline QoQ: -1.1% • Positive free cash flow: $816M • Very high leverage: Debt/EBITDA 10.1x |
| Institutional |
50.0 |
40% | • No insider transactions found in last 90 days (SEC EDGAR Form 4) |
| Macro |
50.0 |
15% | • Sector performance data unavailable |
| Valuation |
50.0 |
78% | • P/E ratio unavailable (negative earnings) |
| Momentum |
23.0 |
95% | • Death cross: MA50 (483.05) < MA200 (526.88) • RSI approaching oversold: 36.4 • MACD bearish: -15.6415 < signal -14.9657 • Weak 20-day momentum: -15.7% |
Score History
showing 7 of 28 runs
| Date (UTC) | Score | Recommendation | Confidence | Modules |
|---|---|---|---|---|
| May 18, 14:18 | 50.3 | WATCH | 71% | 8 |
| May 17, 09:15 | 50.3 | WATCH | 71% | 8 |
| May 16, 12:26 | 50.3 | WATCH | 71% | 8 |
| May 15, 11:16 | 49.9 | IGNORE | 72% | 8 |
| May 14, 10:10 | 50.2 | WATCH | 72% | 8 |
| May 13, 09:16 | 51.3 | WATCH | 71% | 8 |
| May 12, 09:44 | 51.1 | WATCH | 72% | 8 |